George T Grossberg is an expert in Psychiatry at Saint Louis University School of Medicine (United States). As of October 2026, ScienceLeadR ranks George T Grossberg in the top 1% of experts worldwide for Alzheimer Disease, Dementia and Neurocognitive Disorders. George T Grossberg has authored 298 publications, the most recent in 2026, and is an investigator in 7 clinical trials. SLR score: 1,072 (community average: 125). How the SLR is computed.

LeadR Profile

George T Grossberg Saint Louis University School of Medicine United States
1 072 ScienceLeadR Reputation 1072
Network Map

Psychiatry

Subspecialties: Neurology - Geriatrics - Pharmacy

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1998 - 2026

Source: PubMed

Saint Louis University School of Medicine

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 298

Citations

Citations: 14 126 1st author: 40 Last author: 170 Unique author: 11


Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Nicotinic Acetylcholine Receptor Modulation Distinguishes Clinical Benefits of Galantamine in Alzheimer's Disease.
PMID 42688663
Sage Open Aging20260
Understanding and managing agitation in neurocognitive disorders: Recent insights and global perspectives.
PMID 42486765 — geriatric psychiatry, mental disorders, neurocognitive disorders
Int Psychogeriatr20262
Validation and Reliability of the "SLU-AMSAD" Depression Scale in Individuals With Dementia.
PMID 42413154 — long-term care, depression, dementia, neuropsychological tests, caregivers
J Am Med Dir Assoc20260
Pharmacotherapeutic landscape for the management of Agitation associated with Alzheimer's disease.
PMID 42013076 — geriatric psychiatry, bupropion, safety, alzheimer disease, caregivers, drug therapy, dextromethorphan, therapeutics
Expert Opin Pharmacother20260
Brexpiprazole for treating agitation in different groups of people with Alzheimer's dementia: a plain language summary.
PMID 41689409 — language, dementia, antipsychotic agents, neurodegenerative diseases
Neurodegener Dis Manag20260

Clinical Studies 7

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

Phase 3 5
Phase 4 2

By status:

Completed 6
Terminated 1

By type:

Interventional 7

By Monocentric/Multicentric:

monocentric 2
multicentric2to4 0
multicentric5to9 0
multicentricup10 5

Main Topics

LeadR Networks

Main global connection map